7 minute read
Mar. 13, 2024
Inaxaplin: A Breakthrough APOL1 Channel Inhibitor for a Genetically Defined Kidney Disease
inaxaplin (VX-147)
oral, apolipoprotein L1 channel inhibitor Ph. II/III candidate for chronic kidney disease HTS/MetID-enabled optimization New England Journal of Medicine, March 2023 Vertex Pharmaceuticals, Boston, MA
Author:
Loading...
